RxDoctor Payments Data

Gloria Gonzales, MD

Internal Medicine · West Valley City, UTNPI 1942235916

Payments from drug & device makers

$4,424in general payments, 2019–2025

Across 279 payments — averaging $15.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$670
  • Novo Nordisk$296
  • Pfizer$292
  • GSK$280
  • Astellas Pharma US Inc$267
  • Amgen$261
  • plus $2K from 42 others

What the payments were for

  • Food & beverage$4,40099%
  • Education$50%
  • Other$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,424 in reported general payments places this provider in the 85th percentile of 496 internal medicine providers in Utah.

See all internal medicine providers in Utah

Medicare billing

Part B allowed, 2024
$106,651
Medicare patients
209
Services billed
1,363

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide114$129,314
JardianceEmpagliflozin86$106,587
EliquisApixaban85$90,425
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog55$79,951
MounjaroTirzepatide52$68,212
TrulicityDulaglutide52$64,220
FarxigaDapagliflozin Propanediol29$32,874
Tresiba Flextouch U-100Insulin Degludec35$31,908
XareltoRivaroxaban30$27,771
Lantus SolostarInsulin Glargine,hum.Rec.Anlog101$18,280
Humalog Kwikpen U-100Insulin Lispro47$12,050
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$11,740
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$11,237
Stiolto RespimatTiotropium Br/Olodaterol Hcl14$10,773
MyrbetriqMirabegron12$10,712

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$222$132,432104 claims
Novo NordiskOzempic$296$129,314114 claims
Boehringer IngelheimJardiance, Stiolto Respimat$670$117,361100 claims
PfizerEliquis$292$90,42585 claims
AstraZenecaFarxiga, Symbicort$208$35,56440 claims
Johnson & JohnsonXarelto$137$27,77130 claims
GSKTrelegy Ellipta$280$11,74018 claims
Astellas Pharma US IncMyrbetriq$267$10,71212 claims
MerckJanuvia$166$10,31214 claims
Sanofi-aventis U.S. LLCLantus$140$7,89134 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 496 internal medicine providers in Utah.

Other internal medicine in West Valley City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →